|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2010-5-20
|
|
pubmed:abstractText |
NGR-hTNF consists of human tumor necrosis factor alpha (hTNF-alpha) fused to the tumor-homing peptide asparagine-glycine-arginine (NGR) able to selectively bind an aminopeptidase N isoform overexpressed on tumor blood vessels. Hypervascularity is a prominent and poor-prognosis feature of malignant pleural mesothelioma (MPM). Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BajettaEmilioE,
pubmed-author:BordignonClaudioC,
pubmed-author:BruzziPaoloP,
pubmed-author:Caligaris-CappioFedericoF,
pubmed-author:CeresoliGiovanni LGL,
pubmed-author:CitterioGiovanniG,
pubmed-author:De BraudFilippo GFG,
pubmed-author:De PasTommaso MTM,
pubmed-author:De VincenzoFabioF,
pubmed-author:FontanaFlorianaF,
pubmed-author:Grazia ViganòMariaM,
pubmed-author:GregorcVanesaV,
pubmed-author:LambiaseAntonioA,
pubmed-author:RossoniGildaG,
pubmed-author:SantoroArmandoA,
pubmed-author:SimonelliMatteoM,
pubmed-author:SpreaficoAnnaA,
pubmed-author:ZilemboNicolettaN,
pubmed-author:ZucaliPaolo APA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2604-11
|
|
pubmed:meshHeading |
pubmed-meshheading:20406925-Aged,
pubmed-meshheading:20406925-Aged, 80 and over,
pubmed-meshheading:20406925-Cohort Studies,
pubmed-meshheading:20406925-Disease-Free Survival,
pubmed-meshheading:20406925-Female,
pubmed-meshheading:20406925-Humans,
pubmed-meshheading:20406925-Male,
pubmed-meshheading:20406925-Mesothelioma,
pubmed-meshheading:20406925-Middle Aged,
pubmed-meshheading:20406925-Pleural Neoplasms,
pubmed-meshheading:20406925-Recombinant Fusion Proteins,
pubmed-meshheading:20406925-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
|
|
pubmed:affiliation |
Department of Oncology, Istituto Scientifico San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
